GEN #16 Therapeutic Monoclonal Antibodies unfinished

Card Set Information

Author:
HUSOP2014
ID:
139096
Filename:
GEN #16 Therapeutic Monoclonal Antibodies unfinished
Updated:
2012-03-26 10:35:41
Tags:
HUSOP GEN EXAM2
Folders:

Description:
GEN #16 Therapeutic Monoclonal Antibodies
Show Answers:

Home > Flashcards > Print Preview

The flashcards below were created by user HUSOP2014 on FreezingBlue Flashcards. What would you like to do?


  1. Monospecific antibodies are produced by cells that all originate from a single _________ cell
    hydridoma
  2. The only major mouse monoclonal antibody available for human administration is ______
    OKT3
  3. OKT3 is an ____________ and therefore minimizes ___________
    • immunosuppressant
    • immunoreactivity
  4. The 2 types of monoclonal antibodies are _______ which ends in _____ and ________ which ends in _______
    • Chimeric
    • ximab
    • Humanized
    • umab
  5. Chimeric antibodies are composed of _________ sequence the rest human antibody sequence
    ~ 30% mouse protein
  6. In chimeric monoclonal antibodies the V-region remains as _______ , while the remaining protein is ________ antibody
    sequence
    • mouse
    • human
  7. Humanized monoclonal antibodies are composed of ______ mouse protein
    ~10%
  8. In humanized monoclonal antibodies just the ______ is taken from the mouse
    CDRs (complementarity-determining regions)
  9. Proteins are expressed in eukaryotic cells due to _________
    requirements
    glycosylation
  10. From the _______ sequences, one can identify the CDR limits because they are flanked by conserved ___ and _____ chain sequences
    • cDNA
    • L and H
  11. 6 pairs of _________ are generated for PCR amplification of the ________
    • PCR primers
    • 6 CDRS
  12. ____________ ________ is used to sequentially introduce the CDRs into the human homolog
    oligonucleotide-directed mutagenesis
  13. After _____ cycles of mutation, the ______ that is essentially human, with binding sites coded for by the _________
    • 6
    • cDNA
    • mouse DNA
  14. What agent is associated with VEGF and used to treat colorectal cancer
    Bevacizumab
  15. Two primary mechanisms for how antibodies are able to kill cells
    • Antibody-dependent cellular cytotoxicity (ADCC)
    • Complement-mediated cytotoxicity (CDC)
  16. Gemtuzumab is associated with what antigen & what is it used to treat
    • CD33
    • Acute myeloid leukemia
  17. Antibody-dependent cellular cytotoxicity (ADCC) uses _______ to induce apoptosis in targeted
    cells by the release of ________, ___________ and
    ___________
    • NK-cells
    • perforins
    • granzymes
    • IFN-γ
  18. What agent is used to treat T-cell mycosis fungoides, and what antigen is it associated with
    • Daclizumab
    • CD25 α subunit
  19. Complement-mediated cytotoxicity (CDC) uses complement to bind the _______ and then insert into the _________ to
    form the ______________.
    • antibody
    • tumor cell
    • membrane attack complex
  20. Complement-mediated cytotoxicity (CDC) results in disruption of the ___________ of the tumor cell.
    transmembrane integrity
  21. What agent was initially approved for relapsed indolent lymphomas that increases sensitivity of tumor cells to the apoptotic effects of traditional chemotherapeutic agents
    Rituximab
  22. Rituximab binds to CD20 and activates a ____________ which induces ________ expression and expression of _________ antigen
    • ser/tyrosine protein kinase
    • c-myc
    • MHC class II

What would you like to do?

Home > Flashcards > Print Preview